Summary: motilin-Hse) is a new human motilin analogue synthesized by Escherichia coli using a biotechnological method. In this study, the pharmacokinetic properties of SK-896 after a single in travenous injection or during and after a single constant rate intravenous infusion of rats with 3H-SK-896 were assessed. After intravenous bolus injection of male and female rats with 3H-SK-896 at the dose of 4 ,ug/kg, the plasma levels of immunoreactive radioactivity declined bi-exponentially. No sex difference in pharmacokinetic properties was observed after the intravenous bolus injection. During constant rate in travenous infusion of male rats at the dose of 4µg/kg/h for 20 min, the plasma level of immunoreactive radioactivity increased rapidly, and declined bi-exponentially after the completion of infusion. No significant differences in pharmacokinetic parameters were observed between intravenous bolus injection and in travenous infusion, suggesting that there was essentially no change in the pharmacokinetics by the adminis tration rate. Within 120 h after intravenous bolus injection to male and female rats at the dose of 4µg/kg, 10.9%, 9.55% and 3.84% of administered radioactivity were excreted into urine, feces and expired air in males, against 22.7%, 13.1% and 5.38% in female rats, respectively. Serum protein binding of 3H-SK-896 was 91.4-94.2% in dog, 93.6-96.6% in rat and 96.2-97.0% in human. Binding ratio of 3H-SK-896 to human serum albumin was 84.2-87.0%. Concentration-dependency of 3H-SK-896 binding to serum proteins was not observed over the concentration range studied.
Introduction
SK-896 (Phe-Val-Pro-Ile-Phe-Thr-Tyr-Gly-Glu-Leu Gln-Arg-Leu-Gln-Glu-Lys-Glu-Arg-Asn-Lys-Gly-Gln Hse) , in which leucine replaces methionine at position 13 of human motilin and homoserine is added at the C-ter minal, is a new human motilin analogue. A pharmacolog ical profile of SK-896 reported in rabbits, rats and dogs using in vitro techniques, revealed that it bound the moti lin receptors in the rabbit duodenum and induced con traction of the smooth muscle preparation isolated from the rabbit gastrointestinal tract but not that isolated from the rat or the dog." In addition, in the in vivo study, it was reported that treatment with SK-896 significantly shortened the time of first appearance of interdigestive migrating contractions in stomach and the gastric em ptying time with solid marker in dogs with operative il eus as compared with treatment with prostaglandin F2., which is currently used to treat of gastroparalysis.21 SK 896 has the same pharmacological profile as human moti lin in vitro,') and is more effective than prostaglandin F2. in vivo.2) Clinically, intravenously administered motilin or motilin analogue enhances GI motility without serious side effects,3),41 indicating that SK-896 will be more use ful and effective for the treatment of gastroparalysis af ter abdominal surgery and for diabetes.
The aim of this study was to investigate the phar macokinetics of SK-896 after single intravenous ad ministration of 3H-SK-896 in rats.
Materials and Methods

Materials
SK-896 ([Leu13]motilin-Hse) was synthesized at Sanwa Kagaku Kenkyusho, Co., Ltd. 3H-SK-896 (Tyr 3,5 3H; Phe-Val-Pro-Ile-Phe-Thr-Tyr [3,53H)-Gly-Glu Leu-Gln-Arg-Leu-Gln Glu-Lys-Glu-Arg-Asn-Lys Gly Gln-Hse, 325.8 MBq/mg, 97.7%) was purchased from Daiichi Pure Chemical Co., Ltd. Rabbit anti-human moti lin antiserum was prepared by our laboratory. The an tiserum was shown to react mainly with the C-terminal portion of SK-896 but never with other known gastroin testinal hormones. Aprotinin (Sigma Chemical Co.), Tween 80 (Katayama Chemical Industries, Ltd, Tokyo, Japan), albumin bovine fraction V (Sigma Chemical Co.), and albumin human fraction V (Sigma Chemical Co.) were used. All other chemicals were of reagent grade.
Animals
Sprague-Dawley (SD) rats (SLC Inc., Shizuoka, Japan), 7 weeks old and weighing 226-238 g (male) and 162-173 g (female) were used. The animals were housed in an air-conditioned room at 22 ± 3°C with rela tive humidity of 55 ± 15% and a 12-h light cycle, fed standard laboratory diet (CRF-1, Oriental Yeast, Co., Ltd., Tokyo, Japan) and given water ad libitum. The animals were fasted overnight prior to administration.
Also, male and female Beagle dogs (Kitayama Labes company Ltd., Kyoto, Japan), 22 and 38 months old, weighing 9.3 and 8.2 kg were used for the protein bind ing study.
Subjects
Two healthy male subjects, 35 and 38 years of age, participated in protein binding study after giving their in formed consent. For determination of immunoreactive radioactivity in plasma, 3H-SK-896 was administered to separate groups of rats at 4 ug/kg (1.30 MBq/kg) for in travenous bolus injection and at 4 ug/kg/h (1.30 MBq/ kg/h) over 20 min for intravenous infusion. In these groups, aprotinin was added to blood for a final concen tration of 1000 kallikrein inactivator units (KIU) /ml. Furthermore, because there were many blood collect ing points, the hematocrit values of all rats were meas ured in the final blood collecting point. It was confirmed that the hematocrit value did not decrease significantly.
Preparation of Dosing Solution
Excretion Studies
Male and female rats were housed individually in glass metabolic cages (Metabolica®; Sugiyamagen Iriki, Tokyo, Japan) after intravenous bolus injection of 3H SK-896 at 4 ug/kg (0.65 MBq/kg). Urine, feces and ex pired air were collected separately up to 120 h. For de termination of immunoreactive radioactivity in urine, the urine until 6 h was collected, cooled by ice, and aprotinin was added beforehand to exceed the final concentration of 1000 KIU/ml. Each urinary sample was diluted 20 to 50 ml with distilled water. Fecal samples were homogenized with distilled water after weighing. The expired air was collected by two traps containing about 90 ml of distilled water. The trapped water was diluted to 200 ml with distilled water. After collecting excreta until 120 h, the rats were sacrificed by etherization and the carcasses were solubilized by heating and refluxed in 400 ml of 0.5 N sodium hydroxide and 70 ml of toluene. The water layer of the carcass solution was diluted to 1000 ml with distilled water after neutralization with conc. hydrochloric acid. The toluene layer of the carcass solution was diluted to 100 ml with toluene.
Protein Binding Studies
In vitro bindings of 3H-SK-896 to plasma protein in rats, dogs and humans and human serum albumin (HSA) were determined by the charcoal-dextran precipitation method. 3H-SK-896 was added to the sera or HSA at the range of 1.0-1000 ng/ml (rats, dogs and 4.0% HSA) and 1.0-100 ng/ml (humans). After incuba tion of 300 ul of samples for 15 min at 37°C, 1000 ul of 0.13 M phosphate buffer (pH 7.4) containing 1.5 mg/ml charcoal, 0.15 mg/ml dextran T-70, and 0.1% bovine se rum albumin was added and stirred. Samples were left stand for 30 min at 4°C, then centrifuged, and aliquots of supernatant were measured. Besides the control, sam ples were prepared by adding 0.13 M phosphate buffer (pH 7.4) instead of sera or HSA and measured as described. Protein bindings were calculated as follows: Protein binding= (1-A/ (K x T1)) x 100 T1 : radioactivity in the supernatant T2 : radioactivity in a sample A : charcoal adsorption radioactivity (T2-T1) K : adsorption constant; calculation from the radioactivi ty measurement result in the control sample, K = A/T1 8. Determination of Radioactivity 1) Total Radioactivity Ten-50 ul blood samples were dissolved in 1 ml of sol uene-350 (Packard) and mixed with 10 ml of scintilla tors (ACS 11, Amersham) after decolorization and neu tralization. Then, 10-50 ul plasma samples, 500 ul urina ry samples, 500 ul expired air samples and 200-300 ul toluene layer samples of carcass solution were mixed with 10 ml of ACS II. Two hundred-300 ul of fecal sam ples and 300 ul of the water layer samples of carcass so lution were combusted in a sample oxidizer (ASC-113; Aloka). The radioactivity in each sample was measured by liquid scintillation counter (LSC, LS3801 or LS6000; Beckman). Counting efficiency was assessed by the ex ternal standard method.
2) Volatile Radioactivity Five hundred µl of urinary sample was lyophilized in the scintillation vial, residue was dissolved by 500,ul of distilled water, and then mixed with 10 ml of ACS 11. Two hundred-300,u1 fecal homogenate samples were lyophilized in a paper cup, 200µl of distilled water was added to the lyophilized article and the samples were combusted in a sample oxidizer. The radioactivity (non volatile radioactivity) in each sample was measured with the LSC. The volatile radioactivity was calculated by subtracting the nonvolatile radioactivity from the total radioactivity.
3) Immunoreactive Radioactivity in Plasma or Urine One hundred µl of sample (plasma or urine) and 100µl of 10 mM phosphate buffer saline (pH 7.4) containing 1 BSA, 0.1% sodium azide (sample, buffer A) or 100µl of standard (blank plasma or urine) and 100µl of 3H SK-896 standard solution (0.050, 0.10, 0.20, 0.50, 1.0, 2.0 and 5.0 ng/ml) were added to the assay tube. Then, 100pl of rabbit anti-human motilin antiserum at 1/100 dilution with buffer A was added and incubated for 48 h at 4°C. Antibody bound 3H-SK-896 was precipitated us ing 100µl of rabbit serum at 1/25 dilution and 100µl of goat anti-rabbit IgG (Cappel) at 1/10 dilution. The tubes were incubated for 24 h at 4°C and centrifuged for 20 min at 3000 rpm. After the supernatant was aspirat ed, the precipitation was washed with 500µl of buffer A and re-centrifuged. The precipitation was suspended to 500µl of buffer A and dissolved with 1 ml of soluene 350, mixed with 10 ml of ACS 11 after neutralization, and the radioactivity was measured with the LSC. The calibration curve was analyzed with linear regression and immunoreactive radioactivity level was obtained. All samples were assayed in duplicate.
Pharmacokinetic
Data Analysis The radioactivity level in plasma was expressed as ng equivalent of SK-896 per ml of plasma. The pharmacoki netic parameters were calculated from plasma im munoreactive concentration-time data. The elimination half-life (t1/2) of the elimination phase was estimated us ing the least square method of actual data. The area un der the curve (AUC) and under the moment curve (A UMC) of concentration versus time were determined by the trapezoidal rule and by extrapolating to infinity. Plasma clearance (CLP), mean residence time (MRT;,,f) and volume of distribution at steady state (Vdss) were computed by noncompartmental methods.') The Vdss following intravenous infusion was determined by the following equation: Vdss=dose x MRT/AUC-ko x T2/ (2 x AUC), where ko and T are the infusion rate and infu sion time, respectively.
Statistical Analysis
Statistical significance was performed using the one way layout analysis of variance, Scheffe multiple com parison test and Aspin-Welch's t-test. P values less than 0.05 were considered significant.
Results
Pharmacokinetic
Studies The time courses of blood and plasma levels of total radioactivity, plasma levels of immunoreactive radioac tivity and pharmacokinetic parameters after intravenous bolus injection of male and female rats are shown in Fig.  1 and Table I , respectively. After intravenous bolus in jection, blood and plasma levels of total radioactivity declined within 30-40 min and increased once again wi thin 4-6 h after injection and thereafter decreased slow ly. On the other hand, plasma levels of immunoreactive radioactivity declined bi-exponentially with the elimina tion half-lives (t1/2) of 11.4 min (male) and 13.0 min (fe male). No significant differences in pharmacokinetic parameters (AUC, MRT, CLP, Vdss and t1/2) were ob served between male and female rats. There was no sex difference in pharmacokinetics after single intravenous bolus injection.
The time courses of blood and plasma levels of total radioactivity, plasma levels of immunoreactive radioac tivity and pharmacokinetic parameters during and after intravenous infusion of male rats are shown in Fig. 2 and Table II , respectively. During constant rate intravenous infusion, blood and plasma levels of total radioactivity were increased rapidly. After stopping the infusion, blood and plasma levels of total radioactivity declined wi thin 50 min-1 h, increased once again at 6-8 h, and there after decreased slowly. On the other hand, the plasma immunoreactive radioactivity level was increased rapidly during infusion, and declined bi-exponentially with the t1/2 of 7.80 min after stopping the infusion. No significant differences in pharmacokinetic parameters (CLP, Vdss and t112) were observed between intravenous bolus in jection and constant rate intravenous infusion. There was no essential change in the pharmacokinetics by ad ministration rate.
Excretion Studies
Cumulative excretions of total radioactivity in male and female rats after intravenous bolus injection are shown in Table III . Also, the ratios of the volatile radioactivity fraction to total radioactivity in urine and feces are shown in Table IV and V, respectively. Within 120 h after administration, 10.9%, 9.55% and 3.84% of administered radioactivity were excreted into urine, feces and expired air in male, and 22.7%, 13.1% and 5.38% in female rats, respectively. 73.2°c of the dose remained in the carcasses at 120 h post dosing in male, and 58.9% in female rats, respectively. The ratios of the volatile radioactivity to total radioactivity excreted in u rine and feces increased by the time progress after ad ministration. 96.0% and 61.5°/ of radioactivity excreted into urine and feces at 96-120 h after administration were the volatile fraction in male, and 98.8% and 68.5% in female rats, respectively. Also, the urinary excretion of immunoreactive radioactivity until 6 h was below the lower limit of determination (0.050 ng/ml). In female rats, the radioactivity excreted in urine, feces and ex pired air was 2.1, 1.4 and 1.4 times higher than by male rats. The recovery of radioactivity in male and female rats 
Discussion
In the present study, the pharmacokinetics of SK-896 was investigated after single intravenous administra tions of 3H-SK-896 to rats.
After single intravenous bolus injection of male and fe male rats or after single constant rate intravenous infu sion to male rats, the disappearance of the immunoreac tive radioactivity in plasma was fast and reached un detectable levels 2 h after administration. These results indicate that SK-896 was metabolized rapidly, and total radioactivity detected later than 2 h after administration was the radioactivity of metabolites without im munoreactivity or metabolites that were incorporated into the organism component.
When 3H-SK-896 was intravenously administered to rats, radioactivity was excreted very slowly since 73.2% and 58.90o of the dose remained in the male and female carcasses, respectively, at 120 h postdosing. This was conceivable not only due to late excretion of SK-896, but also because the metabolites incorporated into the organ ism components or metabolites as tritiated water remained in the body. This was supported by the fact that the rate of the volatile radioactivity fraction (the tritiated water) to total radioactivity of the urine and feces increased with time after administration.
On the other hand, in female rats, the radioactivity ex creted in urine, feces and expired air was 2.1, 1.4 and 1.4 times higher, respectively, than in male rats. This sex difference , however, may not be owing to a difference in the excretion process of 3H-SK-896 so much as to a difference in the excretion process of tritiated water af ter a metabolite was recycled in the organism. In male and female rats, 3H-SK-896 or metabolite with im munoreactivity were not excreted into urine; most of the radioactivity excreted into urine 24 h after administra tion was a volatile fraction (tritiated water), and there was no sex difference in the pharmacokinetics of im munoreactive radioactivity in plasma.
The ratios of serum protein bindings of 3H-SK-896 in rat, dogs and human were above 92% at the range of 1.0-1000 ng/ml in vitro, indicating very strong binding of SK-896 to serum protein. The protein binding ratio of HSA is 84.2-87.0% and accounted for 88-89% of the binding rates of human serum, indicating SK-896 was mainly bound to serum albumin.
In conclusion, it was observed in this study that 3H SK-896 would be metabolized and eliminated rapidly af ter intravenous administration. However, the excretion of total radioactivity was slow, presumably because the metabolite was recycled in the body. Also, binding to the serum protein of 3H-SK-896 was strong in rat, dog or human. Comparison with the protein binding ratio of HSA led us to infer that SK-896 was bound to serum al bumin.
